WT1, p53 and hormone receptor expression in uterine serous carcinoma: Correspondence

Histopathology

Volumn 55, Issue 4, 2009, Pages 478-482

  Hirschowitz, Lynn ^a   Ganesan, Raji ^a   McCluggage, W Glenn ^b  

^a BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL GROUP OF HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53; WT1 PROTEIN;

ENDOMETRIUM CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; LETTER; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERUS CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; FEMALE; HUMANS; IRELAND; MASSACHUSETTS; MIDDLE AGED; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UTERINE NEOPLASMS; WT1 PROTEINS;

EID: 70349921323     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03390.x     Document Type: Letter

References (18)

1. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 1983 15 10 17.
2. Matias-Guiu X, Catasus L, Bussaglia E et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum. Pathol. 2001 32 569 577.
3. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J. Clin. Oncol. 2006 24 4783 4791.
4. Doll A, Abal M, Rigau M et al. Novel molecular profiles of endometrial cancer-new light through old windows. J. Steroid Biochem. Mol. Biol. 2008 108 221 229.
5. Macwhinnie N, Monaghan H. The use of P53, PTEN and C-erbB-2 to differentiate uterine serous papillary carcinoma from endometrioid endometrial carcinoma. Int. J. Gynecol. Cancer 2004 14 938 946.
6. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000 88 814 824.
7. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch. 2004 444 213 223.
8. Darvishian F, Hummer AJ, Thaler HT et al. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases. Am. J. Surg. Pathol. 2004 28 1568 1578.
9. Goldstein NS, Uzieblo A. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am. J. Clin. Pathol. 2002 117 541 545.
10. Euscher ED, Malpica A, Deavers MT, Silva EG. Differential expression of WT-1 in serous carcinomas in the peritoneum with or without associated serous carcinoma in endometrial polyps. Am. J. Surg. Pathol. 2005 29 1074 1078.
11. Acs G, Pasha T, Zhang PJ. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int. J. Gynecol. Pathol. 2004 23 110 118.
12. Al-Hussaini M, Stockman A, Foster H, McCluggage WG. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 2004 44 109 115.
13. Egan JA, Ionescu MC, Eapen E, Jones JG, Marshall DS. Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium. Int. J. Gynecol. Pathol. 2004 23 119 122.
14. McCluggage WG. WT1 is of value in ascertaining the site of origin of serous carcinomas within the female genital tract. Int. J. Gynecol. Pathol. 2004 23 97 99.
15. Reid-Nicholson M, Iyengar P, Hummer AJ, Linkov I, Asher M, Soslow RA. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod. Pathol. 2006 19 1091 1100.
16. Chambers JT, Carcangiu ML, Voynick IM, Schwartz PE. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part II: correlation between biochemical and immunohistochemical methods and survival. Am. J. Clin. Pathol. 1990 94 255 260.
17. Creasman WT. Prognostic significance of hormone receptors in endometrial cancer. Cancer 1993 71 1467 1470.
18. Ingram SS, Rosenman J, Heath R, Morgan TM, Moore D, Varia M. The predictive value of progesterone receptor levels in endometrial cancer. Int. J. Radiat. Oncol. Biol. Phys. 1989 17 21 27.